1. Home
  2. BGI vs MBAI Comparison

BGI vs MBAI Comparison

Compare BGI & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birks Group Inc.

BGI

Birks Group Inc.

N/A

Current Price

$0.81

Market Cap

14.1M

Sector

N/A

ML Signal

N/A

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.76

Market Cap

12.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BGI
MBAI
Founded
1879
2004
Country
Canada
Israel
Employees
N/A
85
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
14.1M
12.0M
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
BGI
MBAI
Price
$0.81
$1.76
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
22.9K
72.9K
Earning Date
12-05-2025
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$1.31
52 Week High
$1.57
$3.92

Technical Indicators

Market Signals
Indicator
BGI
MBAI
Relative Strength Index (RSI) 57.08 54.00
Support Level $0.77 $1.38
Resistance Level $0.94 $1.89
Average True Range (ATR) 0.06 0.19
MACD 0.01 0.01
Stochastic Oscillator 88.18 40.85

Price Performance

Historical Comparison
BGI
MBAI

About BGI Birks Group Inc.

Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: